Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | TPO | P07202 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956156 | 0.79 | CDC7 (0.43) | TSHRRAB9ASMN1; SMN2L3MBTL1MPO | |
| SCHEMBL3941256 | 0.78 | KCNH2 (0.50) | RAB9ASMN1; SMN2L3MBTL1NPC1IKBKE | |
| SCHEMBL28141352 | 0.78 | TSHR (0.47) | TSHRRAB9ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL64650 | 0.77 | BACE1 (0.49) | RAB9ASMN1; SMN2MPOMAOBMAPT | |
| SCHEMBL9842140 | 0.75 | TSHR (0.44) | TSHRRAB9ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL3927189 | 0.75 | MAOB (0.50) | RAB9ASMN1; SMN2L3MBTL1IKBKEMAOB | |
| SCHEMBL3937691 | 0.75 | NUDT1 (0.47) | RAB9ASMN1; SMN2L3MBTL1IDO1MPO | |
| SCHEMBL27819434 | 0.74 | TSHR (0.43) | TSHRRAB9ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL3939419 | 0.74 | CYP4F2 (0.54) | RAB9ASMN1; SMN2L3MBTL1MPOMAOB | |
| SCHEMBL23854651 | 0.73 | TSHR (0.50) | TSHRIDO1MPOAGXTTPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659001-A | Aminopyrimidine derivatives and their use in medicine | 广东东阳光药业股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-107743489-B | 7- (morpholin-4-yl) pyrazolo [1,5-a ] pyrimidine derivatives for the treatment of immune, inflammatory or cancer | 赛隆制药股份公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3277687-B1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES OR CANCER | Celon Pharma Sa (PL) | 2019-10-30 | — | — | EP | disclosed |
| US-10138247-B2 | 7-(morpholin-4-yl)pyrazole[1,5-A]pyrimidine derivatives as PI3 kinase inhibitors | CELON PHARMA, S.A. (PL) | 2018-11-27 | — | — | US | disclosed |
| US-20180111939-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER | CELON PHARMA S.A. (PL) | 2018-04-26 | — | — | US | disclosed |
| EP-3277687-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES OR CANCER | CELON PHARMA S.A. (PL) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016157091-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES OR CANCER | CELON PHARMA S.A. (PL) | 2016-10-06 | — | — | WO | disclosed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| CN-102149712-A | Pyrazolo [3,4-b ] pyridine Raf inhibitors | ARRAY BIOPHARMA INC | 2011-08-10 | — | — | CN | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138247-B2 | 7-(morpholin-4-yl)pyrazole[1,5-A]pyrimidine derivatives as PI3 kinase inhibitors | PIK3CA, PIK3C2A, MAP3K2 | TSHR 1937/4885RAB9A 1716/4885SMN1; SMN2 3765/4885 |
| US-20180111939-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER | AFF2, INF2, AFF1 | TSHR 1324/4885RAB9A 2406/4885SMN1; SMN2 3525/4885 |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | TSHR 2257/4885RAB9A 947/4885SMN1; SMN2 2996/4885 |
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | TSHR 1428/4885RAB9A 1699/4885SMN1; SMN2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.